6^th European virtual summit on
Pharmaceutical science

Dr. Elder has nearly 40 years of service within the pharmaceutical industry (Sterling, Syntex and for the last two decades with GSK). He is now an independent CMC consultant and has broad based experience in excipients, biopharmaceutics, drug product and analytical method development. Dr. Elder obtained his PhD in crystallography from the University of Edinburgh. Dr. Elder is a visiting professor at King’s College, London. He is a member of the British Pharmacopoeia. He is the immediate past chairman of JPAG (Joint Pharmaceutical Analysis Group). He is a member of the Editorial Advisory Board for the Journal of Pharmaceutical Sciences. He has published 114 and presented 17 webinars and 133 presentations. He has co-edited one book on the Analytical Characterization and Separation of Oligonucleotides and their Impurities (with George Okafo and Mike Webb) and is editing a second book on the ICH Quality Guidelines (with Andy Teasdale, AZ).

Dr. Elder has a long standing interest in impurities and degradation chemistry. He has played a leading role in the identification, analysis and control of mutagenic impurities. He has been part of EfPIA and PhRMA sub-groups on mutagenic impurities and the PQRA group that investigated the formation and control strategies for alkyl sulfonate impurities. He is interested in the role that excipients play in stabilising/destabilising molecules and the impact that changes in excipient material attributes can have on processability of drug products. He is interested in biopharmaceutics and its role in devising formulation strategies, as well as the more classical role that biopharmaceutics plays in biowaivers, bioavailability and bioequivalence studies. He is interested in clinically relevant specifications and whether dissolution tests (and related specifications) can ever really be robust enough to be used in a QC environment and sensitive enough to be truly predictive of clinical outcomes.

Feng-Huei Lin, Tenure Distinguished Professor, Institute of Biomedical Engineering; Director, Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes (NHRI), Taiwan; Lecture Professor, Dept. of Material Science, Institute of Biomedical Engineering, National Taiwan University (NTU), to its College of Fellows. Dr. Lin was nominated, reviewed, and elected by peers and members of the College of Fellows for outstanding contributions in tissue engineering, regeneration medicine, drug/gene delivery advancement, and biomaterial development for disease treatment and prevention.

Biomaterials, Regenerative Medicine, Tissue Engineering and Nanomedicine

Abyt Surname: Ibraimov Citizenship: Kyrgyz Republic (Kyrgyzstan) Current status: Head of Laboratory of Human Genetics, National Center of Cardiology & Internal Medicine, Education Diploma of higher education, pediatrician, Kyrgyz State Medical Institute, Frunze, Kyrghyzstan, 1964-1970. Postgraduate course. Institute of Medical Genetics, USSR Academy of Medicine, Moscow, USSR, 1970-1974. Ph.D., Institute of Medical Genetics, USSR Academy of Medicine, Moscow, USSR, December, 1974. Ph.D. thesis: "The fine morphology of C group chromosomes in human karyotype". Dr.Sc., Institute of Cytology and Genetics, Siberian Branch of USSR Academy of Sciences, Novosibirsk, USSR, 1985. Dr.Sc., theses: “Chromosomal polymorphism in human populationsâ

Zakharov A.F., Baranovskaya L.I., Ibraimov A.I., Benjush V.A., Demintseva V.S. and Oblapenko N.S. 1974. Differential spiralization along mammalian mitotic chromosomes. II. 5-bromdeoxyuridine and 5-bromdeoxycitidine revealed differentiation in human chromosome. Chromosoma, 44: 343-359. 2. Ibraimov А.I. and Mirrakhimov M.M. 1979. PTC-testing ability in populations living in Kyrghyzia with special reference to hypersensitivity: its relation tо sex and age. Hum. Genet., 46: 97-105. 3. Mirrakhimov M.M. and Ibraimov A.I. 1982. Physiological and certain genetic mechanisms of adaptation of native populations to the high altitude climate of Pamir and Tien-Shan. Proc. Indian Statistical Inst. Golden Jubilee. Intern. Conf. of Human Genetics and Adaptation. Calcutta. p. 81-84. 4. Ibraimov А.I., Mirrakhimov М.М., Nazarenko S.А., Axenrod Е.I. and Akbanova G.А. 1982. Нhuman chromosomal polymorphism. I. Chromosomal Q-polymorphism in Mongoloid populations of Central Asia. Hum. Genet., 60: 1-7. 5

Dr Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an h-index of 65, (ResearchGate STATs (28), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu (220 Public Mentions). The citations past 27 years have accumulated to >4770. Ian James Martins - Semantic Scholar Profile https://www.semanticscholar.org/author/Ian-James-Martins/5258067. Semantic Scholar profile for Ian James Martins, with fewer than 133 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer's Disease ...https://www.researchgate.net/profile/Ian_Martins2 under Ian James Martins’ name places publication Research Interest (1622) with an RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Editorial Team.

Anti-Aging, Global Health and Chronic Disease . Keywords: Anti-Aging Genes, Appetite, Environment, Nutrition, Senescence IMPACT OF PREVIOUS RESEARCH TO THE FIELD OF MEDICINE AND LABORATORY TECHNOLOGY THAT MAY AVOID INADVERTENT ERRORS AND MAY TRANSLATE TO COMMERCIALISATION OF MEDICAL RESEARCH THAT determines CRITICAL HEALTH OUTCOMES. Development of a BLOOD TEST has been of critical interest to the for metabolic disease with relevance to diabetes and neurodegenerative diseases. Interests in Biomarker Research has escalated with relevance to mitochondrial survival and organ disease in diabetes and Alzheimer’s disease. The global chronic disease epidemic is expected to cost Biomarker Research between 15 to 20 billion dollars in the next 20 years. Biomarkers such as Sirtuin 1 are now relevant to mitochondrial apoptosis versus mitochondrial biogenesis and may supersede the various biomarkers for mitochondrial survival relevant to diabetes, Alzheimer’s disease and neurodegenerative disease research Anti-Aging Genes, Appetite, Environment, Nutrition, Senescence.

Russell Elliott, Ph.D., has served as the Vice President of Drug Development since May 2016. Dr. Elliott has over 25 years of industry experience, previously holding positions as Head of Skincare Technology at Lonza Inc. from 2015 to 2016, Head of Product Development at Stiefel (a GSK Company) from 2011 to 2014, Head of the Center of Excellence for Liquids, Cream and Ointments at GSK (UK) from 2007 to 2011, and Principal Scientist at Procter & Gamble from 1992 to 2007. He has filed more than 60 patent applications in the area of skincare formulation. Dr. Elliott has a PhD and MA from The University of Oxford and is a Fellow of the Royal Society of Chemistry

Drug development

Amanda Vickers is a medicinal plant chemist, product developer, and entrepreneur, currently directing a botanical testing and formulation lab in North Carolina. Bent Creek Institute is a nonprofit organization, founded to connect conservation-driven botanical research from the Southern Appalachian Mountains to commercialization opportunities in a rapidly expanding global natural products marketplace. In 2012, BCI launched the US Botanical Safety Lab, which has since helped more than sixty companies to propel new innovative natural products to market and clear major regulatory milestones. Amanda is also a founding partner of a natural body care company, Mountains to Sea, which creates opportunities to experience more nature every day through a line of “pure and wild” products produced by an integrated network of horticulturists, conservationists, wild harvesters, small farmers, artisans and makers deeply engaged in exploring new definitions of purity and wilderness in an age of exponential accelerations in technology, connectivity, climate change and human population growth.

Developing trust networks within natural product supply chains.

Maria Lazaro is a Pharmacist from Complutense University of Madrid. He/She(according to the author’s gender) holds advanced master’s in Biotechnology and Pharmaceutical Management works for Seppic in Human Biologicals department (adjuvants for vaccines and excipients for injectables ) since 2012.

animal health, vaccine manufacture, vaccine development

Dr. Stephen F. Amato has over 25 years of experience in the pharmaceutical, biotechnology and medical device industries. Prior to his position as Faculty Director of Graduate Regulatory Affairs & Life Sciences at Northeastern University, Steve was the Founder and Managing Director of tJun17 Life Sciences, LLC, and also a Managing Director for Cardinal Health Regulatory Sciences (CHRS). As an Executive Director at Anika Therapeutics Steve managed all aspects of the company's product portfolio including regulatory, reimbursement, market segmentation, targeting, positioning, pricing and promotional strategies. From 2000 to 2007 he was the Group Director of Knee Repair at Smith & Nephew Endoscopy where he managed a $140 M orthopedic product portfolio. Earlier in his career, Steve worked for Visible Genetics, where he was responsible for developing and launching genomic molecular diagnostics products used for subtyping Human Papilloma Virus (HPV) and other infectious disease agents. He has also worked with Critical Therapeutics on the development and commercialization of treatments for gram-negative sepsis. Steve holds an AB in Biochemical Sciences from Harvard University, a Ph.D. in Molecular and Cellular Biology from Boston College’s Graduate School of Arts & Sciences, and an MBA from the Carroll School of Graduate Management at Boston College. He has also received the US and EU Regulatory Affairs Certification (RAC) designations and is a Consultant for the Regulatory Affairs Professional Society (RAPS).

Global regulatory affairs